Trial Profile

A clinical study assessing triple combination cohort with VBR + NrtI and ATI-2173

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATI-2173 (Primary) ; Vebicorvir (Primary) ; RNA-directed DNA polymerase inhibitors
Indications Hepatitis B
Focus Adverse reactions
Sponsors Assembly Biosciences

Most Recent Events

20 Jul 2022 According to an Assembly Biosciences media release, the company has discontinued development of vebicorvir based on interim efficacy data from ongoing combination clinical studies.
20 Jul 2022 Status changed from planning to discontinued, according to Assembly Biosciences media release.
04 Jan 2022 According to Assembly Biosciences media release, the company expects to report initial on-treatment data from this study in 2H 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com